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ABSTRACT
Objectives: To investigate the role of factors that
modulate the association between alcohol and mortality,
and to provide estimates of absolute risk of death.
Design: The European Prospective Investigation into
Cancer and nutrition (EPIC).
Setting: 23 centres in 10 countries.
Participants: 380 395 men and women, free of
cancer, diabetes, heart attack or stroke at enrolment,
followed up for 12.6 years on average.
Main outcome measures: 20 453 fatal events, of
which 2053 alcohol-related cancers (ARC, including
cancers of upper aerodigestive tract, liver, colorectal and
female breast), 4187 cardiovascular diseases/coronary
heart disease (CVD/CHD), 856 violent deaths and
injuries. Lifetime alcohol use was assessed at
recruitment.
Results: HRs comparing extreme drinkers (≥30 g/day
in women and ≥60 g/day in men) to moderate drinkers
(0.1–4.9 g/day) were 1.27 (95% CI 1.13 to 1.43) in
women and 1.53 (1.39 to 1.68) in men. Strong
associations were observed for ARC mortality, in men
particularly, and for violent deaths and injuries, in men
only. No associations were observed for CVD/CHD
mortality among drinkers, whereby HRs were higher in
never compared to moderate drinkers. Overall mortality
seemed to be more strongly related to beer than wine
use, particularly in men. The 10-year risks of overall
death for women aged 60 years, drinking more than
30 g/day was 5% and 7%, for never and current
smokers, respectively. Corresponding figures in men
consuming more than 60 g/day were 11% and 18%, in
never and current smokers, respectively. In competing
risks analyses, mortality due to CVD/CHD was more
pronounced than ARC in men, while CVD/CHD and ARC
mortality were of similar magnitude in women.
Conclusions: In this large European cohort, alcohol use
was positively associated with overall mortality, ARC and
violent death and injuries, but marginally to CVD/CHD.
Absolute risks of death observed in EPIC suggest that
alcohol is an important determinant of total mortality.
Strengths and limitations of this study
▪ This study was based on information on dietary
and lifestyle exposure collected in a large pro-
spective investigation of European adults.
▪ Findings are based on 380 395 men and women
(among whom 20 453 fatal events occurred) for
which information on lifetime alcohol use was
available, allowing separate consideration of
former drinkers from lifetime abstainers.
▪ Exclusion of study participants reporting a
morbid condition at baseline, and sensitivity ana-
lyses excluding the first 3 years of follow-up
limited the chance that reverse causality affected
the findings.
▪ Although statistical models included many
potentially relevant adjustment factors, residual
confounding might partially account for the
observed associations.
▪ Average lifetime alcohol consumption was evalu-
ated in this study, whereas it is possible that
specific drinking patterns in particular phases of
life, as well as the effect of binge drinking or
drinking during meals, may also be of particular
relevance for mortality.
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INTRODUCTION
Alcohol intake has been associated with an increased risk
of death from a large list of morbid conditions, including
digestive tract conditions, liver cirrhosis, chronic pancrea-
titis, hypertension, injuries and violence.1–3 In contrast,
moderate alcohol drinking was suggested to be associated
with a reduction in cardiovascular disease (CVD) mortal-
ity.4 5 As for cancer, the International Agency for
Research on Cancer and the World Cancer Research
Fund/American Institute for Cancer Research concluded
that alcohol use is associated with an increased risk to
develop cancers of the upper aerodigestive tract, liver,
colorectal and female breast.6 7 It has been estimated
that alcohol accounted for about 2.7 million annual
deaths and 3.8% of all deaths worldwide,8 9 but the
impact of alcohol on mortality is differential with respect
to speciﬁc causes of diseases.3
Within the European Prospective Investigation into
Cancer and nutrition (EPIC), a recent study showed that
heavy alcohol use was associated with a higher risk of
death from alcohol-related cancer, external causes and
‘other causes’, while no associations were observed for
coronary heart disease and other cardiovascular
diseases.10
In this study, we further investigated associations
between alcohol use and overall and cause-speciﬁc mor-
tality. Notably, potential variability of the relationships
with respect to smoking habits, the type of alcoholic bev-
erages and country was explored. The cumulative prob-
abilities of death were estimated for overall mortality
and, in a competing risks framework, for speciﬁc mortal-
ity causes with respect to levels of alcohol, separately in
men and women. Furthermore, the burden of alcohol
use in relation to a broad group of causes of deaths was
evaluated by means of overall estimates of rate advance-
ment periods, with respect to two alternative scenarios.
METHODS
Study population
EPIC is an on-going multicentre study that has been
described in detail previously.11 From 1992 to 2000,
521 448 individuals, aged 25–70 years were recruited in
the surroundings of 23 centres in 10 European coun-
tries. Most of the participants were recruited from the
general population residing in a given geographic area,
a town or a province. Exceptions were the cohorts of
France (female members of a health insurance scheme
for school employees), Utrecht (breast cancer screening
attendees), Ragusa (blood donors and their spouses)
and Oxford (mainly vegetarian and healthy eaters).
Some characteristics of the study population in the dif-
ferent participating countries are reported in table 1.
Study participants provided informed consent and com-
pleted questionnaires on their diet, lifestyle and medical
history. The study was approved by the relevant ethical
review boards of each centre and the International
Agency of Research on Cancer in Lyon, France.11
Dietary and lifestyle assessment
Diet was assessed at enrolment using validated country-
speciﬁc or centre-speciﬁc dietary questionnaires
designed to capture habitual consumption over the pre-
ceding year. Lifetime alcohol consumption was assessed
based on self-reported weekly consumption of wine,
beer and liquor at ages 20, 30, 40, 50 years in the lifestyle
questionnaire. Information on lifetime alcohol con-
sumption was available for approximately 76% of EPIC
participants.12 Information on smoking status and
duration, physical activity during leisure time, prevalent
conditions at baseline, educational attainment,
anthropometric measures and reproductive history was
obtained using lifestyle questionnaires.
Assessment of causes of death
Vital status and information on cause and date of death
were ascertained using record linkage with cancer regis-
tries, boards of health and death registries (Denmark,
Italy, the Netherlands, Spain, the UK) or by active
follow-up (France Germany, Greece). Data were coded
using the 10th revision of the International Statistical
Classiﬁcation of Diseases, Injuries and Causes of Death
(ICD-10) where the underlying cause is the ofﬁcial
cause of death.
In this work, six different causes of deaths were
selected: cardiovascular disease (CVD) (I00–I99
excluding I20–I25) and coronary heart disease (CHD)
(I20–I25), alcohol-related cancer (ARC), including colo-
rectal cancer (C18–C20), female breast cancer (C50),
upper aerodigestive cancers (UADT, including cancer of
the mouth (C01–C10 without C08=salivary gland), larynx
(C21), pharynx (C11–C14), oesophagus (C15)), violent
deaths and injuries (injury, poisoning and certain other
consequences of external causes (S00–T98); deaths due
to respiratory diseases (J00–J99); a group for all other
causes (including external causes of morbidity and mor-
tality (V01–Y98), unknown causes (R96–R99)).
Statistical analyses
Participants from Denmark (Aarhus, Copenhagen),
France, Germany (Heidelberg, Potsdam), Greece, Italy
(Florence, Varese, Ragusa, Turin), the Netherlands
(Utrecht), Spain (Asturias, Granada, Murcia, Navarra,
San Sebastian) and the UK (Cambridge, Oxford) were
eligible for this analysis. We excluded the entire cohorts
of Naples (Italy), Bilthoven (the Netherlands), Sweden
and Norway because no information on past alcohol use
was collected (n=118 082). Further exclusions concerned
participants with incomplete vital status information
(n=928), who had not ﬁlled out the dietary or lifestyle
questionnaires (n=11 411) and participants whose ratio
of energy intake to estimated energy requirement
(n=7592), calculated in terms of gender, body weight,
height and age, was in the top or bottom 1% in order to
partially reduce the impact of outlier values.13
Participants that at recruitment reported cancer
(n=13 283), diabetes (n=11 240), myocardial infarction
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Table 1 Country-specific and sex-specific number of participants (N), person-years (PY), cause-specific and overall number of deaths
N PY CHD* CVD†
Cancers Other
cancers¶
Violent and
injuries** Resp††
Other
causes‡‡ TotalCountry Breast UADT‡ Liver Colon-rectum Total§
Women
France 65 127 971 127 45 202 62 8 4 27 101 678 115 73 1619 2833
Italy 24 956 306 244 26 87 71 6 12 53 142 293 30 12 120 710
Spain 23 616 323 027 41 50 51 6 9 47 113 243 46 9 119 621
UK 50 251 651 640 387 320 160 30 15 127 332 716 85 161 1091 3092
The Netherlands 14 583 189 531 110 137 58 14 7 78 157 370 20 65 209 1068
Greece 14 391 143 150 139 100 41 2 10 18 71 146 26 27 94 603
Germany 27 098 307 380 56 74 64 12 14 44 134 256 35 25 114 694
Denmark 27 773 328 375 84 143 128 23 17 110 278 648 51 116 548 1868
All 247 795 3 220 474 888 1113 635 101 88 504 1328 3335 408 488 3848 11 489
Men
France – – – – – – – – – – – – – –
Italy 13 471 168 992 53 59 – 8 10 39 57 240 35 13 131 588
Spain 14 089 189 942 136 88 – 34 14 62 110 351 81 42 151 959
UK 20 452 262 720 438 229 – 41 11 68 120 567 88 171 1040 2653
The Netherlands – – – – – – – – – – – – – –
Greece 9726 90 989 193 141 – 12 20 31 63 279 49 54 99 878
Germany 19 743 221 724 167 138 – 37 25 65 127 437 84 35 264 1253
Denmark 24 454 282 622 273 271 – 91 31 126 248 838 111 95 794 2633
All 101 935 1 216 988 1260 926 – 223 111 391 725 2712 448 410 2479 8964
*CHD, coronary heart disease (I20–I25) deaths.
†CVD, cardiovascular disease (I00–I99 except I20–I25) deaths.
‡UADT deaths from upper aerodigestive cancers (including cancer of the mouth (C01–C10 without C08=salivary gland)), larynx (C21), pharynx (C11–C14), oesophagus (C15)).
§Total frequency of alcohol-related cancers.
¶Other cancers: deaths from all other cancers.
**Violent deaths and injuries, including injury, poisoning and certain other consequences of external causes (S00–T98), and external causes of morbidity and mortality (V01–Y98).
††Resp=respiratory diseases (J00–J99).
‡‡All other causes of death.
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or heart disease (n=5266) or stroke (n=3246) were
excluded from the analyses (n=30 665 in total).
Cox proportional hazard models were used to
compute mortality HR, and 95% CIs, for categories of
average lifetime alcohol use; never drinkers, 1–4.9 g/day
(reference category), 5–14.9, 15–29.9, 30–59.9, ≥60 g/day.
In women, the last two alcohol categories were collapsed
into a ≥30 g/day group. Time in the study up to death,
loss or end of follow-up, whichever came ﬁrst was
the primary time variable. The Breslow method was
adopted for handling ties. Models were stratiﬁed by
centre to control for differences in questionnaire
design, follow-up procedures and other centre-speciﬁc
effects.13 Systematic adjustments were undertaken for
age at recruitment, body mass index and height (con-
tinuous), an indicator for participants who quitted
alcohol drinking, time since alcohol quitting (continu-
ous), smoking (never, current with 1–15 cigarettes/day,
current with more than 15 cigarettes/day, former
smoker that quitted less than 10 years before recruit-
ment, former smoker that quitted more than 10 years
before recruitment, current smoker of other than cigar-
ettes, unknown (n=8819)), duration of smoking (con-
tinuous), age at start smoking (less than 19 years, more
than 19 years, unknown (n=39 041)), educational attain-
ment (ﬁve categories of level of schooling: none,
primary, technical or degree or more, unknown
(n=14 223)) as a proxy variable for socioeconomic
status, physical activity (inactive, moderately inactive,
moderately active, active, unknown (n=328)) and energy
intake (continuous). In women the models were further
adjusted for menopausal status (dichotomised as natural
postmenopausal or surgical vs premenopausal or peri-
menopausal, as assessed at baseline), ever use of replace-
ment hormones, and number of full-term pregnancies
(nulliparous, one or two children, more than three,
unknown (n=6482)). Indicator variables speciﬁc to some
of the confounding factors were used to model missing
values, after checking that the parameters associated
with these indicators were not statistically signiﬁcantly
associated with risk of death.
Models for overall and cause-speciﬁc mortality were
ﬁtted, separately for men and women. An overall test of
signiﬁcance of HRs related to alcohol use was
determined by computing p values (pWald) for Wald
test statistics compared with a χ2 distribution with
degrees of freedom equal to the number of alcohol cat-
egories minus one. The proportional hazards assump-
tion in the Cox model was satisﬁed and evaluated via
inclusion into the disease model of interaction terms
between lifetime alcohol and follow-up time. To reduce
the chance of reverse causality, sensitivity analyses
were run excluding the ﬁrst 3 years of follow-up. As
results were not different from those using the entire
cohort, they were not shown. Analyses excluding former
drinkers (4% and 5% of the study populations, in men
and women, respectively) provided very similar results
(results not shown).
Evaluating heterogeneity
Effect modiﬁcation in the relation between alcohol and
mortality by, in turn, smoking status (never, ever),
smoking status (never and current smokers) and recruit-
ment country was assessed. Models with main effects
and interaction terms were ﬁtted and compared with
models with main effects only. The difference in
log-likelihood (likelihood ratio test statistics) was com-
pared to a χ2 distribution with degrees of freedom equal
to the number of interaction terms. HRs for alcohol cat-
egories across levels of interacting variables were com-
puted as linear combinations of main effects and
interactions. Associations with wine and beer use
(each grouped as never, 0.1–2.9 g/day (reference),
3–9.9, 10–19.9, 20–39.9, ≥40 g/day, ≥20 g/day in
women) and total mortality were assessed in mutually
adjusted models. The difference of association for wine
and beer use in relation to overall mortality was assessed
by inspecting the signiﬁcance of the parameter related
to the arithmetic difference of wine and beer use
(expressed on the log-scale plus 1 to deal with abstai-
ners) in a model that also included their arithmetic
sum. When assessing the association for wine (beer)
intake, analyses were restricted to moderate lifetime
drinkers of beer (wine) and spirits (below 3 g/day).
Flexible parametric survival models14 with age as the
time scale were used to evaluate whether the association
between alcohol intake and mortality rate varied by
attained age. The origin of the time scale was set to
30 years as the hazard of death is essentially zero prior
to that age. The baseline cumulative hazard was mod-
elled using restricted cubic splines with three internal
knots placed at evenly spaced centiles of the uncensored
log-survival times in order to ensure that an equivalent
number of deaths occurred between each knot.15
Interactions between alcohol intake and the time scale
were modelled using restricted cubic splines with one
knot placed at the median of uncensored log-survival
times. HRs and differences in survival functions were cal-
culated from the ﬁtted models and plotted against
attained age, along with CIs calculated based on δ
method variance estimates.
Possible departures from linearity in the association
between average lifetime alcohol use and total mortality
were assessed using fractional polynomials,16 a subset of
generalised linear models in which various powers (−2,
−1, −0.5, 0, 0.5, 1, 2, 3) of the covariate(s) of interest
are entered into the linear predictor. Fractional polyno-
mials of order two were consistently used in this work
for lifetime alcohol use.17 Non-linearity was tested com-
paring the difference in log-likelihood of a model with
the fractional polynomials with a model with a linear
term only to a χ2 distribution with three degrees of
freedom.16
Absolute risks
An extension of the Cox proportional hazards model
was employed to ﬁt cause-speciﬁc associations between
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lifetime alcohol use and cause-speciﬁc mortality in a
competing risks framework.18 An augmented data set
was created where the initial data set is replicated a
number of times equal to the different causes of death.
In each replicated data set, competing causes of death
were set to censored observations and the analyses were
stratiﬁed by the event type.19 The relationship between
each confounder variables and cause-speciﬁc mortality
was assumed homogeneous across causes of death. In
this way competing risks were accounted for, and
cumulative cause-speciﬁc and overall mortality curves
were estimated for heavy (greater than 30 and 60 g/day,
in women and men, respectively) and moderate
(0.1–4.9 g/day) drinkers, separately for never and
current smokers.20 Cumulative mortality curves were
obtained for participants aged 60 years, using mean
values for continuous confounding factors and average
frequencies for categorical confounders.
Quantifying the alcohol burden
The burden of alcohol on mortality was quantiﬁed with
estimates of the rate advancement period (RAP),21
according to two scenarios with threshold levels equal to
5 and 15 g/day. For overall and cause-speciﬁc risk of
death, RAP were computed, dividing the log(HR) esti-
mate comparing alcohol users above and the threshold
with alcohol drinkers between 0.1 g/day and the thresh-
old, by the log of the parameter associated with age.
Never alcohol users were not included in the estimation.
Associated 95% CIs were also determined. RAP estimates
express the impact of a given exposure on the risk of
death, by determining the time (in years) by which the
risk of death is anticipated for exposed study participants
compared with non-exposed.
Statistical tests were two-sided, and p values <0.05 were
considered statistically signiﬁcant. All analyses were per-
formed using SAS V.9.222 and Stata V.12.1.23
RESULTS
Baseline characteristics
The current analysis was based on 247 795 female and
101 935 male study participants. The median age at
enrolment was 52 years for women and 53 years for
men. Study participants were followed on average
12.6 years, accumulating 4 800 585 person-years,
during which a total of 20 453 fatal events were recorded
(table 1).
Drinking patterns differed substantially between men
and women (table 2). In women, 10% (n=25 146) of
participants were lifetime never drinkers, while 45%
(n=112 281) and 2% (n=6042) were moderate (0.1–
4.9 g/day) and heavy users (>30 g/day), respectively.
Conversely, only 1.5% (n=1600) of men reported having
never consumed alcohol, 14% (n=14 287) were moder-
ate drinkers, while 29% (n=29 124) were heavy or
extreme drinkers (30–59.9 and ≥60 g/day).
Furthermore, the vast majority of women who were
regular drinkers (total alcohol intake ≥10 g/day) drank
predominantly wine (91%), rather than beer (9%),
while regular drinkers in men drank beer (46%) and
wine (54%) in similar proportions.
Compared to never and moderate drinkers, women
with higher alcohol use had higher levels of education
and physical activity, and were more likely to be current
smokers or premenopausal/perimenopausal. Never
alcohol users were less likely to have used hormonal
replacement therapy than alcohol drinkers. In men, the
trends were somewhat less apparent. Heavy and extreme
alcohol users (≥30 g/day) were more often current
smokers, attained lower educational level and had
higher energy intake levels, compared with moderate
drinkers. Never drinkers were physically less active than
alcohol drinkers.
Lifetime alcohol and total mortality
Lifetime average alcohol use was strongly associated
with total mortality, in that never and heavy drinkers
(≥30 g/day) had notably higher mortality rates than did
light to moderate drinkers (0.1–4.9 g/day), a pattern
that was consistently apparent among female and male
study participants (ﬁgure 1). The HR comparing never
and heavy drinkers with moderate drinkers in women
was 1.26 (95% CI 1.18 to 1.35) and 1.27 (1.13 to 1.43),
respectively. The corresponding HRs among men were
1.29 (1.10 to 1.51) for never drinkers, 1.15 (1.06 to 1.24)
for heavy drinkers and 1.53 (1.39 to 1.68) for extreme
drinkers (≥60 g/day).
Lifetime alcohol and cause-specific mortality
In men, extreme alcohol use was associated with mortal-
ity due to ARCs (HR≥60 vs ref=2.62 1.90 to 3.62), other
cancers (1.34 1.13 to 1.59), violent deaths and injuries
(1.93 1.27 to 2.91) and other causes (1.98 1.67 to 2.34).
With the exception of the category for never drinkers,
alcohol intake was not associated with CVD or CHD
mortality, in women and men. Among women, heavy
drinkers displayed HR≥30 vs ref equal to 1.49 (1.07, 2.06)
for ARCs. Respiratory diseases were not associated with
lifetime alcohol in women, while results were suggestive
of an increased risk in extreme alcohol users compared
with moderate users in men (see online supplementary
ﬁgure S1). Dose–response relationships evaluated with
fractional polynomials are displayed in online supple-
mentary ﬁgures S2 and S3, for women and men,
respectively.
Evaluating heterogeneity
In both sexes, alcohol-related HRs for overall mortality
were of similar magnitude in never and current smokers
(table 3). Analyses conducted by smoking intensity (never
vs heavy smokers, ie, more than 15 cigarettes/day) pro-
duced very similar evidence (results not shown).
Cause-speciﬁc analyses showed mostly homogeneous
alcohol-related HRs by smoking status (results not shown).
In women, beer use was more strongly related than wine
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Table 2 Characteristics of the study population at recruitment, according to amount and type of alcohol intake (g/day) in the EPIC study*
Characteristics Unit Never drinkers
Lifetime drinkers
Total‡
Wine
consumers§
Beer
consumers‡0.1–4.9 5–14.9 15–29.9 30–59.9† >60†
Women
Number of participants n 25 146 112 281 77 147 27 179 6042 – 247 795 85 965 8748
Person-years – 330 854 1 460 315 998 547 352 220 78 538 – 3 220 474 1 124 546 110 761
Age at recruitment Years 52 (9) 52 (10) 51 (10) 49 (11) 47 (11) – 51 (38–63) 52 (9) 46 (12)
Lifetime alcohol intake g/day 0 (–) 2 (2) 9 (3) 20 (4) 43 (21) – 7 (0–17) 12 (9) 11 (9)
Educational attainment¶ % 14 22 27 33 37 – 25 28 28
Current smokers % 13 14 18 24 31 – 17 17 28
Body mass index kg/m2 27 (5) 25 (5) 25 (4) 24 (4) 24 (4) – 25 (20–31) 24 (4) 25 (4)
Height cm 158 (6) 161 (6) 162 (6) 163 (7) 164 (6) – 162 (153–170) 162 (6) 163 (7)
(Moderately) active % 26 39 44 44 43 – 40 42 42
Ever use of HRT** % 16 25 29 28 25 – 25 50 34
Postmenopausal status†† % 50 49 49 44 38 – 48 29 20
Energy intake kcal/day 1848 (537) 1943 (537) 2015 (536) 2090 (552) 2195 (602) – 1978 (542) 2046 (544) 1976 (545)
Men
Number of participants n 1600 14 287 28 875 28 049 20 788 8336 101 935 26 137 22 136
Person-years – 19 114 171 739 345 899 333 784 247 612 98 841 1 216 989 317 937 259 934
Age at recruitment Years 53 (11) 53 (11) 53 (9) 52 (9) 52 (9) 52 (9) 53 (41–64) 53 (9) 52 (10)
Lifetime alcohol intake g/day 0 (–) 2 (2) 10 (3) 22 (4) 42 (8) 94 (45) 25 (3–45) 30 (27) 22 (25)
Educational attainment¶ % 21 30 31 32 26 14 29 22 27
Current smokers % 28 22 25 30 36 49 30 31 33
Body mass index kg/m2 27 (4) 26 (4) 26 (3) 27 (3) 27 (4) 28 (4) 27 (22–31) 27 (4) 27 (4)
Height cm 171 (7) 174 (7) 175 (7) 175 (7) 174 (7) 172 (7) 174 (165–183) 172 (7) 175 (7)
(Moderately) active % 42 46 50 52 52 50 50 48 52
Energy intake kcal/day 2284 (675) 2267 (650) 2315 (618) 2417 (622) 2569 (646) 2789 (716) 2427 (656) 2487 (652) 2369 (651)
*Means±SDs are presented for continuous variables, frequencies for categorical variables.
†In women the last alcohol category is ≥30 g/day.
‡For continuous variables (with exception of energy intake), mean (10–90th centile) values are reported.
§Study participants consuming more than 10 g/day of wine (or beer), and consuming less than 3 g/day of beer (or wine).
¶Participants with a university degree or more.
**HRT=hormonal replacement therapy.
††Postmenopausal women plus women who underwent an ovariectomy.
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to overall mortality for amounts greater than 3 g/day com-
pared with the reference category (0.1–2.9 g/day).
Lifetime never wine and beer users displayed higher risks
than moderate drinkers. The associations between lifetime
alcohol and overall risk of mortality were differential
across country of origin in men (pheterogeneity=0.012) but
not in women (pheterogeneity=0.511), as reported in online
supplementary ﬁgures S4 and S5, with stronger relation-
ships observed in Northern European countries compared
with Southern European countries.
The HR≥60 vs ref for men was more pronounced at
earlier ages, and were close to one as attained age
approached 90 years (plikelihood-ratio for age-varying vs age
invariant parameterisation=0.003); however, extreme male
drinkers exhibited lower cumulative survival probability
than the reference group throughout the lifespan (see
online supplementary ﬁgure S6). No such age-varying
association was apparent for women (plikelihood-ratio=0.80).
Absolute risks
The 10-year risk of death at the age of 60 years for heavy
drinkers was 5% and 7% in women (≥30 g/day), and
11% and 18% in men (≥60 g/day), for never and
current smokers, respectively (ﬁgure 2). Corresponding
ﬁgures in moderate drinkers (0.1–4.9 g/day) were 3%
and 4% in women, and 5% and 8% in men. Based on a
competing risks analysis, it was estimated that, at the age
of 60 years, a female lifetime heavy alcohol drinker and
smoker had a 10-year risk of death of 1% for ARC, 1.2%
for CVD/CHD and 0.2% for violent death and injuries,
as displayed in ﬁgure 3. Corresponding ﬁgures for males
(≥60 g/day) were 2.2% (ARC), 5% (CVD/CHD) and
1% (violent death and injuries). Risks for moderate
drinkers for ARC, CVD/CHD and violent death and
injuries were 0.8%, 1.2%, 0.2% and 0.9%, 4%, 0.3%, in
women and men, respectively. Consistently lower risks
were observed for never smoker individuals, with
Figure 1 Number of deaths, person-years (PY) and multivariable HRs (Models were stratified by centre. Systematic adjustment
was undertaken for age at recruitment, body mass index and height, former drinking, time since alcohol quitting, smoking status,
duration of smoking, age at start smoking, educational attainment and energy intake. In women adjustment was undertaken for
menopausal status, ever use of replacement hormones and number of full-term pregnancies.) with 95% CIs and p value of the
Wald test for statistical significance for overall and cause-specific mortality by categories of lifetime alcohol use, in women and
men.
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Table 3 Sex-specific number of deaths, HR* and 95% CI for overall mortality by categories of lifetime alcohol use (g/day), by smoking status (never and current smokers),
and type of alcoholic beverage
Overall
Women
pheterog‡ Overall
Men
pheterog‡
Never smokers Current smokers Never smokers Current smokers
Deaths HR† (95% CI) Deaths HR† (95% CI) Deaths HR† (95% CI) Deaths HR† (95% CI)
Never 1009 1.34 (1.24 to 1.45) 154 1.72 (1.32 to 2.23) Never 84 1.50 (1.19 to 1.21) 58 2.09 (1.26 to 3.47)
0.1–4.9 3046 1 Ref 1021 1.53 (1.23 to 1.90) 0.1–4.9 457 1 Ref 367 1.62 (1.04 to 2.53)
5–14.9 1550 1.04 (0.98 to 1.11) 874 1.51 (1.21 to 1.88) 5–14.9 538 0.93 (0.82 to 1.06) 799 1.45 (0.93 to 2.25)
15–29.9 397 1.04 (0.94 to 1.16) 435 1.74 (1.38 to 2.19) 15–29.9 369 1.00 (0.87 to 1.16) 927 1.66 (1.06 to 2.58)
≥ 30 82 1.29 (1.03 to 1.61) 140 2.08 (1.59 to 2.73) 30–59.9 254 1.22 (1.23 to 1.43) 857 1.83 (1.17 to 2.84)
pWald§ <0.001 <0.001 0.150 ≥ 60 107 1.56 (1.25 to 1.95) 590 2.43 (1.55 to 3.80)
pWald§ <0.001 <0.001 0.864
Wine use Beer use
pdifference**
Wine use Beer use
pdifference**Deaths HR¶ (95% CI) Deaths HR¶ (95% CI) Deaths HR¶ (95% CI) Deaths HR¶ (95% CI)
Never 2156 1.15 (1.09 to 1.22) 5041 1.06 (1.02 to 1.12) Never 1064 1.21 (1.12 to 1.30) 975 1.07 (0.98 to 1.16)
0.1–2.9 5109 1 Ref 5477 1 Ref 0.1–2.9 3266 1 Ref 2959 1 Ref
3–9.9 2813 0.96 (0.92 to 1.01) 787 1.15 (1.07 to 1.24) 3–9.9 2139 0.92 (0.87 to 0.97) 2486 1.04 (0.98 to 1.10)
10–19.9 1057 1.00 (0.93 to 1.07) 147 1.50 (1.27 to 1.77) 10–19.9 1040 0.96 (0.89 to 1.03) 1248 1.12 (1.04 to 1.20)
≥ 20 354 1.14 (1.02 to 1.27) 37 1.47 (1.06 to 2.04) 20–39.9 814 1.03 (0.95 to 1.13) 877 1.41 (1.30 to 1.54)
pWald§ <0.001 <0.001 <0.001 ≥40 641 1.22 (1.10 to 1.35) 419 1.86 (1.66 to 2.09)
pWald§ <0.001 <0.001 <0.001
*Models were stratified by centre. Systematic adjustment was undertaken for age at recruitment, BMI and height, former drinking, time since alcohol quitting, smoking status, duration of smoking,
age at start smoking, educational attainment and energy intake. In women adjustment was undertaken for menopausal status, ever use of replacement hormones and number of full-term
pregnancies.
†Models included interaction terms between lifetime alcohol use and a smoking indicator (0=never smokers; 1=current smokers), keeping the reference category the group of moderate alcohol
users (0.1–4.9 g/day) among never smokers, whereas former smokers and participants with unknown smoking status were excluded.
‡Pheterogeneity: difference in HRs assessed comparing the log-likelihood of models with and without interaction terms between alcohol and smoking status to a four and five degrees of
freedom (dof) χ2 distribution, in women and men, respectively.
§pWald: determined using a Wald test for contrasts according to a χ
2 distribution with four and five degrees of freedom, in women and men, respectively.
¶Models on wine and beer uses were mutually adjusted, and also included spirits/liquors use.
**pdifference expresses the difference of associations between wine and beer use, determined evaluating the significance of the parameter estimate γ2 in a model that included, other than the list
of confounders, the terms γ1(X1+X2)/2+γ2(X1−X2)/2, with X1=log(wine use+1) and X2=log(beer use+1).
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estimates equal to 0.5%, 0.7% and 0.1% in women, and
1%, 2.1% and 0.3% in men.
Rate advancement period
The impact of lifetime alcohol on overall and cause-
speciﬁc mortality was estimated with RAP values (table 4).
In women, RAP for overall mortality were equal to
0.36 years (95% CI −0.05 to 0.76) and 0.83 (0.26 to 1.39),
for the 5 and 15 g/day scenario, respectively. In men, RAP
values were equal to 0.15 (−0.48 to 0.76) and 1.42 (0.96 to
1.89), for 5 and 15 g/day, respectively. RAP values were
sizeable for mortality due to ARC (5.03: 3.07, 7.00) and
violent death and injuries (11.83: 3.92, 18.17) in the
second scenario.
DISCUSSION
In this large European prospective study, the association
between alcohol use and overall and cause-speciﬁc risk
of death was evaluated in eight European populations.
When accounting for potential confounding factors,
average lifetime alcohol use was strongly associated with
overall mortality, whereas lifetime never alcohol users
consistently displayed a higher risk of death compared
with moderate drinkers. These results are in agreement
with a recent evaluation of alcohol and cause-speciﬁc
mortality in EPIC.10 With respect to this recent study,10
further analyses were conducted to deeply investigate
the role of factors that modulate the association between
alcohol use and the risk of death, notably smoking and
types of alcoholic beverage. Estimates of 10-year risk of
death in relation to levels of alcohol use were provided.
This study has several strengths. It was conducted
using a large prospective cohort, where dietary and life-
style exposure information were collected on disease-
free individuals. Information on lifetime alcohol use was
available on 76% of the cohort, allowing separate consid-
eration of former drinkers and lifetime abstainers.
Further, exclusion of study participants reporting a
morbid condition at baseline, and sensitivity analyses
excluding the ﬁrst 3 years of follow-up suggest that
reverse causality is unlikely to have affected the results.
One potential weakness of this study is that, although
statistical models included many potentially relevant
adjustment factors, residual confounding might partially
account for the observed associations. In addition,
average lifetime alcohol consumption was used through-
out this study, whereby it is possible that speciﬁc drink-
ing patterns in particular phases of life,10 as well as the
effect of binge drinking or drinking during meals may
be of particular relevance for mortality.
A recent Russian study found a strong relationship
between vodka and risk of death.24 While an apparent
J-shaped relationship between alcohol use and mortality
has been reported,25 26 the interpretation of this pattern
is the subject of some controversy. It has been suggested
that alcohol abstinence does not truly entail greater risk
of death than moderate use, and that misclassiﬁcation of
alcohol quantity and lack of accuracy in reporting preva-
lent morbid conditions at baseline in the group of never
drinkers27 could explain the excess risks observed. This
reasoning motivated our choice of considering moderate
alcohol drinkers, as the reference category throughout
this work. Moreover, residual and unmeasured con-
founding are plausible drivers of the association.28
These suggestions are supported by our ﬁndings that
never drinkers are at increased risk of death due to vio-
lence and injury. This implausible association casts con-
siderable doubt on the veracity of the apparent
increased risk of death among never drinkers.
The overall mortality HR for men with extreme versus
moderate alcohol use was greater at younger ages, and
approached one as age increased towards 90 years. This
result reﬂects the comparatively low incidence of death
through middle age. Consideration of the absolute risk
of death, however, suggests that moderate drinkers have
a substantial cumulative survival advantage over extreme
drinkers throughout the adult lifespan. It has been sug-
gested that wine drinking could be more favourably asso-
ciated than other alcoholic beverages to the risk of CHD
and some cancers.29–32 In this study beer use displayed
more apparent risk patterns than wine consumption,
particularly in men. Although we believe that this
ﬁnding is relevant, we call for cautious interpretations of
these results, as the lifestyle proﬁle of wine and beer
drinkers is profoundly different. The associations
Figure 2 Sex-specific plots displaying cumulative
probabilities of death due to overall mortality, for heavy
(=30 g/day in women and=60 g/day in men, continuous line)
and moderate lifetime use (0.1–4.9 g/day) (dotted line), in
smokers (black line) and never smokers (grey line), for study
participants aged 60 years.
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between alcohol and mortality were heterogeneous
across countries in men, but not in women. This could
be due to the larger amount of alcohol consumed in
men than in women, naturally increasing the variability
of exposure and the statistical power to detect associa-
tions, and of the larger variability characterising drink-
ing habits in men, such as binge drinking, drinking
during meals and other societal aspects. Although no
Figure 3 In competing risks analyses, sex-specific plots displaying cumulative probabilities of death due to CVD/CHD (red),
alcohol-related cancers (blue) and violent death and injuries (green), for study participants aged 60 years according to heavy
(=30 g/day in women and=60 g/day in men, continuous line) and moderate (0.1–4.9 g/day, dotted lines) lifetime alcohol use in
current and never smokers in the EPIC study.
Table 4 Sex-specific estimates of rate advancement period (RAP) and associated 95% CI for overall and mortality due to
ARCs, CVD/CHD and injuries and violent deaths, related to two scenarios of lifetime alcohol use. RAP estimates express the
impact of a given exposure on the risk of death, by determining the time (in years) by which the risk of death is anticipated for
study participants exposed, for example, all drinkers more than the threshold (5 or 15 g/day in Scenarios I and II,
respectively), compared to non-exposed, that is, individuals drinking between 0.1 g/day and the threshold*
Scenario I Scenario II
Threshold 5 g/day Threshold 15 g/day
RAP (years) 95% CI RAP (years) 95% CI
Women
Overall 0.36 −0.05 to 0.76 0.83 0.26 to 1.39
CVD/CHD 0.23 −0.46 to 0.92 0.08 −0.96 to 1.14
Alcohol-related cancers 1.28 −0.86 to 3.41 1.90 −1.00 to 4.81
Injuries and violent deaths −2.69 −6.85 to 1.47 −0.20 −5.85 to 5.46
Men
Overall 0.15 −0.48 to 0.76 1.42 0.96 to 1.89
CVD/CHD −0.53 −1.57 to 0.50 −0.01 −0.82 to 0.81
Alcohol-related cancers 2.59 −0.30 to 5.49 5.03 3.07 to 7.00
Injuries and violent deaths 7.59 −2.82 to 18.02 11.83 3.92 to 18.17
*Never lifetime alcohol users did not enter into the estimation process.
CVD/CHD, cardiovascular diseases coronary heart disease; RAP, rate advancement period.
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heterogeneity was observed by smoking status, mortality
among smokers was higher than the mortality among
non-smokers, so the absolute increase in risk associated
with alcohol intake is more extreme among smokers.
This differential increase in cumulative probability of
death emphasises the central role of tobacco as a risk
factor for mortality, as well as the potential extra harm
of increased alcohol consumption.
In the EPIC study, although associations with alcohol
were mostly apparent for ARC and violent death and
injuries, absolute risks were highest for CVD/CHD in
men, while CVD/CHD and ARC risks were of similar
magnitude in women. In general, as individuals report-
ing a prevalent condition at recruitment (either cancer,
diabetes, heart attack or stroke) were excluded from the
analysis in an effort to minimise reverse causality, our
estimates of absolute risks of death are possibly underes-
timated. RAP values were estimated to appreciate the
risk beneﬁt of alcohol drinkers if they were to modify
their exposure, according to a counterfactual scen-
ario.21 33 Consistently in men and women, RAP values
for overall mortality were larger when the reference cat-
egory was set to 0.1–15 g/day than when using a thresh-
old of 5 g/day, thus indicating that, based on the EPIC
study, the beneﬁt for drinkers could be largest if their
intake is reduced to levels below 15 g/day. These results
are in line with ﬁndings of a recent work in the UK
population, where the reduction of overall mortality was
estimated to be optimised for alcohol reduction up to a
median population level of 5 g/day.34
In a large prospective study in Europe, lifetime alcohol
intake was signiﬁcantly associated with overall and
ARC-speciﬁc mortality. In men, positive associations were
observed for violent deaths and injuries, while CVD and
CHD deaths were not associated with alcohol use among
drinkers. Our ﬁndings suggest that these associations do
not differ between never and current smokers, and were
stronger for beer than for wine drinkers.
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